Central American polyvalent snake venom antisera solution for injection 10ml ampoules

Venom-based therapies are hindered by traditional discovery methods that are costly and inconsistent. Immunoinformatics offers a faster route to identify immunogenic epitopes, yet its application to venom proteins remains limited. We conducted a systematic review under PRISMA-2020 guidelines to identify studies predicting venom toxin epitopes computationally and validating them experimentally. Risk of bias was evaluated using a custom 20-question checklist. Following our systematic search, 11 articles met inclusion criteria. Multitool prediction strategies consistently outperformed single-tool approaches, particularly when structural and sequence-based models were combined. Experimental validations confirmed immunogenicity through diverse assays, but reporting inconsistencies, limited negative data, and variable study designs impaired direct comparison. Toxin family and structural data availability emerged as key factors influencing prediction success. In silico epitope prediction, combined with experimental validation, holds strong promise for advancing venom research. Our systematic bias assessment underscores the critical need for standardized frameworks to evaluate dataset selection, algorithm parameters, and validation rigor in computational epitope discovery. Moreover, the field must urgently address data scarcity, standardize validation protocols, and expand venom-specific training datasets to fully realize the promise of immunoinformatics-driven discovery.

Abstract licence: CC BY

Snake envenomation remains an important yet neglected medical problem in many countries, with around five million people affected, and over a hundred thousand deaths annually. Plasma-derived antivenoms are the main therapeutic agent available. Monovalent antivenoms are produced via the immunization of large animals, e.g., horses, with one venom, after which the horse serum can neutralize the homologous venom, with minimal or no cross neutralization against other venoms. It is necessary, therefore, for the culprit snake to be identified, so that the appropriate specific antivenom can be selected. Polyvalent antivenoms (pAVs) are produced via immunization with a number of snake venoms, and the serum can neutralize all the venoms used in its production. Thus, pAVs can be used to treat several venoms from a country/region, and the identification of the culprit snake is not necessary. There are various parameters and processes involved in the production of pAVs, depending on the requirements and resources available. Most commercial pAVs use a mixture of both elapid and viperid venoms as immunogens, while some pAVs use either elapid or viperid venoms. Some pAVs are produced through the mixing of more than one monovalent or polyvalent antivenom. These various types of pAVs have their own characteristics, and have benefits and drawbacks. The major benefits of pAVs are the wide coverage of many medically important venoms, including many heterologous venoms. They also remove the need to identify the culprit snake, and they can be produced at a lower cost than several monovalent antivenoms. Interesting polyvalent antivenoms, termed ‘syndromic pAVs’ (s-pAVs), have recently gained attention. They are produced for use according to the syndromes manifested in snakebite patients. The venoms that produce these syndromes are used as immunogens in the production of ‘syndromic antivenoms’. For example, ‘neurotoxic polyvalent antivenom’ and ‘hematotoxic polyvalent antivenom’ are produced using the neurotoxic elapid and hematotoxic viperid venoms as immunogens, respectively. They were first marketed by the Thai Red Cross in 2012, and have since gained attention as a possible therapeutic modality to help solve the problem of snakebite envenomation globally. The merits of these s-pAVs, including their efficacy and wide paraspecificities, are discussed.

Abstract licence: CC BY 4.0

Snakebite envenomation, especially from hemotoxic species such as Daboia russelii and Echis carinatus, remains a significant public health challenge in the northern Indian states of Punjab, Haryana, Uttar Pradesh, Uttarakhand, and Himachal Pradesh. Despite the availability of polyvalent anti-snake venom (ASV), inconsistent dosing strategies, delayed administration, and disparities in healthcare contribute to high morbidity and mortality rates. This review examines optimal ASV dosing protocols, clinical outcomes, and host-specific factors that influence the therapeutic efficacy in hemotoxic envenomation. Drawing from regional epidemiological data, toxicological insights, and clinical studies, the review underscores the influence of bite-to-needle intervals, ASV administration routes, and infrastructural readiness on patient survival. Notably, intravenous administration proves superior, while early intervention significantly reduces systemic complications. The study identifies key gaps in national guidelines, particularly the mismatch between regional venom variability and available ASV formulations. It also explores emerging alternatives like Varespladib and monoclonal antivenoms. Methodologically, the review adopts a narrative synthesis of peer-reviewed literature and policy frameworks. It concludes that standardizing ASV treatment based on regional evidence, enhancing healthcare capacity, and integrating public health education are essential to improving outcomes. The findings support the need for locally tailored, patient-centric treatment protocols and stronger public health systems to mitigate snakebite-related burdens.

Abstract licence: CC BY